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FACTORS ASSOCIATED WITH INTENSITY OF END-OF-LIFE CARE FOR 
PATIENTS WITH ACUTE MYELOID LEUKEMIA 
DAGNY VAUGHN 
ABSTRACT 
INTRODUCTION: Older patients with AML (> 60 years) often receive intensive EOL 
care including hospitalizations and chemotherapy close to death. Intensive EOL care has 
been shown to increase emotional and financial burdens for patients and families, while 
often not aligning with patients’ preferences. However, factors associated with the 
intensity of EOL care in this population are unknown.  
 
OBJECTIVES: There is a need to better understand the factors associated with intense 
EOL care, in hopes of providing more informed, high-quality EOL care in line with 
patient preferences and decreasing burdens associated with unnecessary healthcare. We 
aim to describe the associations between the intensity of EOL care, patient demographics, 
and baseline psychological distress in older patients with AML.  
 
METHODS: We conducted a secondary analysis of two supportive care studies 
including 168 deceased older patients with AML. We assessed patients’ demographics, 
quality of life (QOL) [Functional Assessment Cancer Therapy-Leukemia], and anxiety 
and depression symptoms [Hospital Anxiety and Depression Scale (HADS); Patient 
Health Questionnaire (PHQ-9)] at the time of diagnosis. We used multivariate logistic 
regression models to examine the association among demographic factors, patient-
	
vi	
reported outcomes, and the following EOL care outcomes abstracted from the electronic 
health record: 1) hospitalizations in the last 7 days of life; 2) receipt of chemotherapy in 
the last 30 days of life; and 3) hospice utilization.  
 
RESULTS: The median age of the cohort was 69 (range 20-100), and the majority were 
males (63.7% 107/168). Overall, 66.7% (110/165) of patients were hospitalized in the last 
7 days of life, 51.8% (71/137) received chemotherapy in the last 30 days of life, and 
40.7% (70/168) utilized hospice services. In multivariate models, higher education (OR = 
1.54, SE=0.24, P=0.006), and elevated depression symptoms [PHQ-9: OR=1.09, 
SE=0.04, P=0.028] at the time of diagnosis were associated with higher odds of being 
hospitalized in the last 7 days of life. In contrast, higher QOL at diagnosis [OR=0.98, 
SE=0.01, P=0.009] was associated with lower odds of being hospitalized in the last 7 
days of life. Depression symptoms at the time of diagnosis as measured by the HADS 
was the only factor associated with the receipt of chemotherapy in the last 30 days of life 
[HADS-Depression: OR=1.10, SE=0.05, P=0.042]. Patients factors were not associated 
with hospice utilization. 
 
CONCLUSIONS:  Older patients with AML who are more educated and report elevated 
depression symptoms and lower QOL at the time of diagnosis were more likely to receive 
intensive EOL care. These findings identify a population at the time of diagnosis of AML 
who are at higher risk for hospitalizations and chemotherapy use at the EOL and who 
may benefit from targeted supportive care interventions. 
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Until recently, the majority of patients in the US died in the hospital, despite most 
expressing a preference to die at home.1-3 Even though home has now become the most 
common place of death in the US, nearly 30% of patient deaths still occur in hospital 
settings.2 In addition to spending the last moments of life in the hospital, many patients 
experience frequent interactions with healthcare settings for much of their time before 
death.4 This high amount of healthcare utilization at the end-of-life (EOL) is particularly 
common in patients suffering from cancer, with over half of these patients being admitted 
to the hospital in the last month of life.5, 6  For cancers such as Acute Myeloid Leukemia 
(AML), a life-threatening hematologic malignancy, high rates of intense care and death in 
hospital settings are even more frequent.7, 8 Given the established discrepancy between 
patient preferences and outcomes at the EOL, there is a need to better understand the 
factors that are associated with intense EOL care, in hopes of providing more informed, 
high-quality EOL care in line with patient preferences and decreasing burdens associated 
with unnecessary healthcare.  
 
Defining Intense EOL Care  
 
The EOL for an ill individual can be a time marked by emotional burden,9 high 
healthcare costs and utilization,4 and difficult decision-making.10, 11 A major factor that 
impacts these experiences is the quality of care received and the goals of that care. 




focuses mostly or exclusively on disease-modifying treatments at the expense of good 
symptom management and/or advance care planning”.12  Because determining the best 
course of care for a patient is highly individual and influenced by many factors, the 
“aggressiveness” of care will be discussed as “intensity” of care in this study, as not to 
imply that such care is negative in every situation. However, intense EOL care has been 
broadly shown to negatively impact patients’ quality-of-life (QOL),13 perceptions of 
quality-of-care,14 and families’ experiences,13-15 while not always providing better health 
outcomes.15-16 Additionally, more intense EOL care is associated with higher financial 
burdens, especially for older patients with multiple comorbidities.4  
Six “poor quality” EOL care indicators were identified in a pioneering study 
utilizing literature review, focus groups with cancer patients and family members, and an 
expert panel.17 These indicators have since been widely used to study the type of EOL 
care delivered across countries and disease types.5, 15, 18 Similar indicators have also been 
used to describe healthcare utilization in non-cancer patient populations.4 These 
indicators were defined as measures of a healthcare system’s ability to provide high 
quality EOL care, but not as measures to analyze the care of an individual patient.17 
These indicators include: the use of chemotherapy in the last month of life, a high number 
of emergency department (ED) visits, hospital admissions, or intensive care unit (ICU) 
stays at the EOL, lack of hospice use, and death in the hospital.17. Importantly, these 
indicators have now been accepted by professional societies including The American 
Society of Clinical Oncology (ASCO) and the American Academy of Hospice and 




quality of care at the EOL.19 A summary of the rationale behind each group of indicators, 
as explained by Earle et al., is included below:  
• Chemotherapy Usage at the EOL  
In the defining paper by Earle et al., the continued, late usage of anticancer 
therapies was described as potentially leading to greater toxicity than clinical 
benefit. Continued conversations regarding new anticancer therapies despite 
successive therapeutic failures was noted to be potentially distracting from 
conversations about prognosis with providers. In focus groups conducted by this 
study team, patients and families both felt that they should be given the option to 
try treatments regardless of effectiveness, however they also endorsed the concept 
of discontinuing therapy at an appropriate time before death. Failure to do so was 
said to give the family an inaccurate idea of how advanced the disease had 
become, leading to greater shock at the time of death. Typically, chemotherapy 
usage at the EOL is measured as new therapies or doses occurring within the last 
30 days of life.7, 15, 17,  
• Emergency Department (ED) Visits, Hospital Admissions, Intensive Care Unit 
(ICU) stays at the EOL  
High numbers of ED visits, unplanned hospital admissions, and stays in the ICU 
are thought to be indicative of intense care, a lack of symptom management, and 
insufficient use of home services or hospice care. Additionally, it is thought that 
many of these visits and admissions could be prevented with high-quality EOL 




specialty palliative care and hospice services. This would allow the patient to 
spend more time at home through the EOL, which is known to be preferred 
amongst most patients. Typically, rates of admissions, ED visits, and ICU stays 
are measured in the last 30 days of life and/or the last 7 days of life.7, 15, 17  
• Lack of Hospice Use and Death in the Hospital  
Given the well-established fact that most patients prefer to die at home, it is 
thought that a higher proportion of patients dying outside of the hospital setting is 
a sign of high quality EOL care.1, 17, 20 Along that line, hospice care at the EOL 
specifically is thought of as a sign of high quality care because of its focus on 
symptom relief and QOL rather than active intervention.21, 22 Hospice care is 
associated with less aggressive and costly care at the EOL,23-26 and has been 
shown to be related to better patient QOL and lower caregiver depression and 
complicated bereavement.26-30 However, studies have shown that patients only 
derive these benefits if they receive hospice care at a minimum of 7 days before 
death,26, 29, 30 so referral very close to death is not considered beneficial.17, 26 
 
According to these indicators, the quality of EOL care is defined overall by how 
frequently a patient interacts with acute healthcare settings and how much focus is given 
to symptom-reduction, QOL improvement, and patient preferences. Palliative and 
hospice care is known to specialize in symptom management and QOL improvement, and 
it can also be provided in the home setting. 21, 22 Thus, its usage is commonly associated 




settings or in pursuit of treatment with curative intent at the EOL is indicative of poor 
quality EOL care, as defined by Earle et al. Thus, intensity of care at the EOL, defined by 
the above indicators, is thought of as inversely related to quality of care at the EOL. 
 
Healthcare Utilization and EOL Care Among Cancer Patients  
Patients with cancer are known to have high healthcare utilization throughout the 
course of disease, with many experiencing intense EOL care.5, 18, 32 In a study of patients 
with solid tumors, thirty percent had at least one indicator of intense EOL care, with more 
than half of that group having multiple indicators.5 In another study of cancer patients, 
22.4% experienced at least one indicator of intense EOL care.18 Additionally, rates of 
intense EOL care have increased in recent decades, specifically in frequencies of ED 
visits, hospitalizations, ICU stays, and late chemotherapy usage.5, 18 Concurrently, the 
rates of cancer patients admitted to hospice has also increased, which is thought to be 
inversely correlated with indicators of intense care.5 However, high numbers of patients 
were found to be admitted to hospice closer to death, which is not considered favorable 
and rather a result of delayed referral.17  
High healthcare utilization is expected for the cancer patient population due to the 
high symptom burden and complications many patients face. Patients are often 
hospitalized for symptoms such as pain,6, 33 fever,34 dyspnea,33 neurological symptoms,33 
and fatigue,6, 31 with specific symptoms varying largely by cancer type. In a study of 
patients with gastrointestinal (GI) cancer, 53% of their hospitalizations were due to 




these hospitalizations were determined to be unnecessary,34 pointing to the possibility of 
reducing the amount of healthcare utilization the cancer patient population experiences.  
 
Healthcare Utilization and EOL Care in Hematologic Malignancies 
Hematologic malignancies, including leukemias, myelomas, and lymphomas, are 
known to be associated with especially high rates of healthcare utilization and intense 
EOL care, compared with other cancer types.7, 15, 18, 31, 35-37  In one study, patients with 
hematologic malignancies had nearly double the odds of experiencing intense EOL care 
as other cancer types studied.18 Results of another study (presented in Table 1) show that 
54% of patients with hematologic malignancies experienced ED visits in the last month 
of life, 81% experienced hospital admissions, 39% were admitted to the ICU, and 47% 
died in the hospital.7 Furthermore, patients with hematologic malignancies are less likely 
to be admitted to a palliative care unit or receive palliative care consultation in the last 
month of life, compared to other cancer types.7, 31, 37, 38 
 Many factors contribute to high health care utilization and intense EOL care for 
patients with hematologic malignancies including 1) the curable potential of these 
illnesses; 2) prognostic uncertainty regarding the illness trajectory; and 3) hematologists-
oncologists’ desire to give more aggressive treatment for patients with hematologic 
malignancies.31 These qualities especially impact the low rates of timely referral to 
hospice care and/or involvement of specialty palliative care services.31 The curable 




between curative and palliative phases of treatment, lead to many patients receiving 
supportive care interventions very close to death or not at all.31  
These malignancies are also associated with very high physical symptom burden 
and need for intervention to manage the disease, both of which contribute to levels of 
healthcare utilization.31, 35 In addition to symptoms such as fatigue, pain, dyspnea, and 
neuropathy experienced across many cancer types, patients with hematologic 
malignancies also commonly experience cytopenias, infections, and coagulopathies, 
which lead to frequent hospitalizations and acute care visits for management.7 Notably, 
higher rates of clinically significant fatigue and drowsiness are reported among patients 
with hematological malignancies, with fatigue affecting 80-90% of patients with acute 
leukemia, myelodysplastic syndrome, and multiple myeloma.31, 39 Higher psychological 
distress scores are also common for patients with hematologic malignancies, which 
compounds the number of symptoms this population faces.35  A recent analysis even 
suggests that patients with hematological malignancies are more distressed than patients 
of any other cancer type.31, 40  
Patients with hematologic malignancies are more likely to experience every 
category of intense EOL care, including the use of chemotherapy near the EOL, frequent 
hospital admissions, a lack of palliative care or hospice care utilization, and a higher risk 
of dying in an acute care setting.7, 15, 31, 36. 37, 41 In line with what is known about the 
effects of intense EOL care on patient QOL, patients with hematologic malignancies who 
die in the ICU or hospital have greater distress and worse QOL, along with higher risk of 




The present study will specifically focus on AML, a hematologic malignancy. 
The pathology, diagnosis, and treatment of AML, patients’ experiences, and healthcare 
utilization patterns will be discussed in detail below. 
 
Table 1: Quality of EOL Care Indicators, rates in solid tumors vs. hematologic 
malignancies. Taken from Hui et al., “Quality of End-of-Life Care in Patients with 
Hematologic Malignancies”, 2014.7     
 








Within last 30 days of life: 







     2 or more ED visits………….. 83 (12) 17 (15) 0.35 
     Any hospital admission……... 333 (47) 91 (81) < 0.001 
     2 or more hospital admissions. 73 (10) 26 (23) <0.001 
     Hospital death……………….. 110 (16) 53 (47) < 0.001 
     ICU admission………………. 55 (8) 44 (39) <0.001 
     ICU death……………………. 30 (4) 37 (33) <0.001 
     Chemotherapy use…………... 98 (14) 49 (43) <0.001 
     Palliative care unit admission.. 116 (17) 9 (8) 0.020 
Composite score for aggressive EOL 
care: 
     0……………………………... 
     1……………………………... 
     2……………………………... 
     3……………………………... 






















Acute Myeloid Leukemia 
Prevalence and Prognosis  
 
There are approximately 21,000 new cases of AML diagnosed in the United 
States each year, which represents 30% of all new cases of leukemia.43, 44  Despite being 
the most common type of leukemia, an individual’s chance of being diagnosed with AML 
is relatively rare, with a prevalence of <5 per 10,000.43, 45 However, the disease is 
characterized by a poor prognosis, with only about 28% of diagnosed adults surviving 5 
years or more.43 AML is more common in older patients, with the median age at 
diagnosis being 68 and over 50% of cases being diagnosed in people over the age of 65.43 
This heavily contributes to the poor survival rate of the disease, as a person is more likely 
to have unfavorable cytogenetics, poorer performance status, and multidrug resistance 
with advanced age.46 For people over the age of 59, the median survival time is just 8 to 
10 months.46 
Pathophysiology 
In a healthy adult, bone marrow produces red blood cells, platelets, and a variety 
of white blood cells through a process called hematopoiesis. Hematopoiesis occurs when 
self-renewing hematopoietic stem cells (HSCs) divide into more specialized types of 
cells, eventually giving rise to all cellular components of blood. An HSC first divides into 
either a lymphoid progenitor cell or a myeloid progenitor cell, creating two specific cell 
lineages as shown in Figure 1.47-49 When working correctly, this process should give rise 
to appropriate amounts of each cell type depending on the needs of the body. However, 





Figure 1: Hematopoiesis. Adapted from Terese Winslow (assisted by Lydia Kibiuk), 
February 22, 2020.48 
 
AML occurs when abnormal myeloid progenitor cells (myeloblasts) accumulate 
in the bone marrow and fail to divide into their normal specialized cell types.45 This 
accumulation interferes with the production of red blood cells, platelets, and white blood 
cells, causing neutropenia (a low concentration of neutrophils), anemia (a low number of 
red blood cells), and thrombocytopenia (a low number of platelets).45, 47 As a result, 
symptoms of AML commonly include fevers and infections due to a deficiency of 
infection-fighting immune cells, fatigue due to the reduction of oxygen-carrying red 






Diagnosis and Treatment Options  
AML is most often diagnosed by observation of abnormal blood counts and 
confirmation by bone marrow aspirate. Diagnosis is typically followed by various 
analyses to detect the patient’s specific cytogenetic profile and molecular abnormalities.50 
Treatment goals and therapy selections are determined based on the patient’s age, 
medical fitness, and specific cytogenetic profile, and usually fall into one of the following 
categories:  
• Intensive Induction Chemotherapy: Also known as “7+3” therapy, this 
selection of chemotherapy is chosen for younger patients or those who are 
determined to be medically fit and able to withstand its toxicity. Administration is 
done in a hospital setting during a long-term admission. This treatment is pursued 
with curative intent and is often followed by a hematopoietic stem-cell transplant 
(HSCT) if remission is reached.51  
• Low-Intensity Chemotherapy: This type of chemotherapy is usually pursued for 
patients who are not medically fit enough to withstand induction therapy. It may 
be administered in the inpatient or outpatient setting. Low-intensity therapy helps 
manage AML, but typically does not lead to a cure.51 
• Supportive Care Only: Supportive care only may be determined to be the most 
appropriate for a patient, given their fitness, age, and goals of care. With this 
option, symptoms of AML are controlled by frequent blood transfusions, 





Figure 2: Peripheral blood smear of a patient with AML. Taken from Samip 
Master, MD; Nebu Koshy, MD via the American Society of Hematology Image 
Bank.52 
 
Experience of Diagnosis and Symptom Burden  
 
Diagnosis of acute leukemia can be particularly traumatic as it is often 
characterized by abrupt onset and an immediate threat to life without urgent treatment.53-
55 Often, patients are diagnosed after mild to non-existent symptoms, causing the 
diagnosis to feel extremely unexpected and shocking.55 It is common for patients to 
present to their primary care physician who detects abnormal blood counts and quickly 
refers them to the ED. Patients who are able to withstand intensive chemotherapy face a 
sudden 4 to 6 week long hospitalization, which quickly removes them from all aspects of 
their normal life and routine. Those who require low-intensity therapy face a likely 




“You’re kind of in shock. I mean I went into the emergency unit, they were trying 
to find out what was wrong with me. I didn’t pack a bag or anything like that. 
And I wound up staying there overnight, and being shipped to this hospital. 
Didn’t see my apartment for months. I had no idea I wasn’t even going to see my 
apartment for months. Like, they just picked me up and took me, took my life 
away.” (Participant #5014) 55 
 
After the shock of diagnosis, patients face the significant toxicity, symptom burden, and 
distress of undergoing chemotherapy.54, 56 A course of intensive chemotherapy commonly 
causes significant pain and discomfort, with the most frequent distressing physical 
symptoms being fever, oral mucositis, loss of appetite, nausea and vomiting, taste and 
smell changes, weight and hair loss.56  
The experience of AML diagnosis and treatment also heavily impacts patients 
psychologically. Beyond the initial shock of diagnosis, the early phase of treatment can 
be marked by an overwhelming sense of loss, fear, and uncertainty.54 Baseline health-
related QOL is reportedly lower for patients with AML than for other cancer patients or 
the general population.45 For patients receiving intensive therapy, QOL has been shown 
to decline 2 weeks into intensive treatment before improving.57, 58 A longitudinal study by 
El-Jawahri et al. found that approximately a third of patients report clinically significant 
depression and anxiety symptoms shortly after initiation of either intensive or low-
intensity chemotherapy.58 Much like QOL improves over time, patients’ anxiety 
symptoms also improved over time, though depression symptoms did not significantly 
change.44 In fact, psychosocial wellbeing of patients who survive treatment has been 




Symptom burden, QOL, and psychological distress experienced by AML patients 
significantly worsens with proximity to death.44 The most severe symptoms experienced 
at the EOL were fatigue, inability to engage in hard word or activity, and anxiety.32 
Additionally, many patients rely on blood transfusions at the EOL.32 Because of this, 
several studies have specifically called for increased integration of palliative care services 
into the EOL care of AML patients.44, 31, 58  
 
Figure 3: Longitudinal patient QOL during initial chemotherapy treatment for 
AML as measured by El-Jawahri et al. using the FACT-Leu. CI = 95% Confidence 
Interval. QOL improved over course of treatment (β= 0.32, 95%CI [0.07, 0.57], p= 
0.013), with no significant differences between treatment intensity (β= -1.22, 95%CI 
[-8.67, 6.23], p=0.748) or in the slope of QOL change over time (β= -0.25, 95%CI [-









Figure 4: Longitudinal patient anxiety and depression symptoms during 
chemotherapy for AML as measured by El-Jawahri et al. using the HADS. CI = 
95% Confidence Interval. Depression symptoms did not change significantly over 
time (β= -0.03, 95%CI= [-0.07, 0.01]. p= 0.132), while anxiety symptoms decreased 
(β= -0.08, 95%CI [-0.11, -0.04], p= <0.001). There were no significant differences 
between treatment intensity or slope of change over time. Taken from El-Jawahri et 










Healthcare Utilization and EOL Care in AML 
Patients diagnosed with AML experience some of the highest rates of healthcare 
utilization and intense EOL care, as described across hematologic malignancies. 7, 8, 15, 18, 
31, 35-37 However, only a few studies have specifically observed healthcare utilization and 
EOL outcomes in this population.8, 44  In one study of healthcare utilization among 330 
older AML patients, a median number of 4.2 hospitalizations (range, 0-18) was found, 
with nearly 30% of patient being admitted to the ICU. Almost 90% of this cohort died 
within 2 years of follow-up, with 61% dying in the hospital. Patients that died were found 
to have spent a mean of 42.1% of their life after diagnosis in the hospital or attending 
outpatient clinic visits.8 Lowe et al. observed equally high rates of healthcare utilization 
at the EOL among AML patients, with 24 out of 26 patients hospitalized in the last month 
of life, spending a median of 14 days in the hospital. Of those, 13 were admitted to the 
ICU and 7 died there.44  
As shown across hematologic malignancies in general, palliative care services are 
rarely utilized for patients with AML.8, 31, 44 In the first study described above, only 
14.2% of patients received a palliative care consultation, and for those who died, the 
median time from palliative care consultation to death was only 7 days.8 Hospice services 
were also under-utilized, with only 22.1% of patients receiving hospice services before 
death and of those, only about half had a hospice length of stay (LOS) greater than 7 




Factors Associated with Intensity of EOL Care  
In order to provide the most appropriate and highest quality care at the EOL, it is 
important to identify factors that may be associated with high healthcare utilization and 
intense care at the EOL, but few studies have done this.5, 18 As discussed previously, 
cancer type is related to rates of healthcare utilization and intense EOL care, with 
hematologic cancers experiencing the highest rates.18 Female sex 5, 18 and increased age 5, 
18 are associated with decreased odds of intensive EOL care 5, while comorbidity is 
predictive of intensive care.5, 18 Interestingly, location also impacts risk of receiving 
intense EOL care. Patients receiving care in a teaching hospital or in a region with more 
teaching hospitals per capital have a higher likelihood of receiving intense EOL care 
(Earle). On the other hand, a higher density of hospices is associated with a decrease in 
the likelihood of experiencing intense EOL care indicators.5 In a study taking place in 
Canada, rurality was also predictive of intense EOL care.18  
 In line with the argument for higher utilization and earlier integration of palliative 
care services, one study found that EOL discussions lower the likelihood of acute or 
intensive care at the EOL and promote greater use of hospice care.13 This effect was 
found to be even greater when EOL discussed occur more than 30 days before death.13    
 Overall, studies examining the factors associated with the intensity of EOL care in 
patients with cancer are lacking. There is an even greater deficiency of studies examining 
these factors in patients with hematological malignancies and in those with AML 




in these populations, which are known to experience high rate of intense EOL care 
compared to patients with other types of cancer.   
Specific Aims of the Present Study 
Patients diagnosed with AML are known to have high healthcare utilization and to 
undergo intense care towards the EOL.7, 8, 18, 44  Previous research has described these 
outcomes and efforts have been proposed to improve care at the EOL through models 
such as early integrated palliative care.8, 44 However, factors that are associated with high 
healthcare utilization and intense care at the EOL have not been well-described for the 
AML patient population specifically. In fact, few studies to date have examined such 
factors and those that have focused on the general cancer population. Identification of 
associated factors may allow for earlier intervention, more informed approaches to EOL 
care, and greater respect of patient preferences. Additionally, approaching EOL care from 
this informed standpoint can help reduce unnecessary or unwanted care at the EOL, 
improving QOL for patients and families, while also reducing unnecessary burdens for 
patients, families, and healthcare systems.  
This study is a retrospective analysis of medical record information and patient-
reported outcomes collected from two randomized control trials run by Dr. Areej El-
Jawahri at MGH. The specific aims of this study are to:  
1. Further describe healthcare utilization and intensity of EOL care received by 




2. Describe the associations between patient-reported demographics and intensity of 
EOL care.  
3. Describe the associations between patient-reported outcomes, including anxiety 






We retrospectively analyzed the electronic medical records (EMRs) of 260 
patients at five major academic medical centers (Massachusetts General Hospital [MGH], 
Dana Farber Cancer Institute [DFCI], Duke University Hospital [Duke], the Hospital of 
the University of Pennsylvania [UPenn], and Ohio State University Hospital [OSU]). All 
patients had been consented to one of two supportive care research studies led by Dr. 
Areej El-Jawahri at the MGH. All patients enrolled in these studies had a diagnosis of 
AML and met all eligibility and exclusion criteria, which are outlined in Table 2. All 
patients enrolled on these studies completed questionnaires regarding their demographics, 
QOL, and psychological distress. At the time of informed consent for both studies, 
patients agreed to have their medical records reviewed for data collection. Both studies 
included in this analysis were approved by the Dana Farber Harvard Cancer Center 
Institutional Review Board. Of the 260 EMRs reviewed, 168 deceased patients were 
ultimately selected for inclusion in this analysis. 92 patients were excluded due to 
transferring care or if they were not deceased.  
 
Measures of Patient Report Outcomes 
As part of both research studies included in this analysis, patients completed 
baseline questionnaires designed to assess their self-reported demographics, baseline 
QOL, baseline levels of depression and anxiety, symptom burden, and prognostic 




by patients in the inpatient or outpatient setting and within the first five days of treatment 
for AML. Baseline patient-reported outcomes questionnaires included the following: 
 
1) Patient demographics: This included age, sex, race, relationship 
status, religion, education level, and average household income. 
(Appendix I) 	
2) Patient-reported QOL: We used the Functional Assessment of 
Cancer Therapy [FACT-Leu], a highly-vetted and widely-used 
instrument comprised of 17 items that measure leukemia-specific 
health-related QOL.68 The FACT-Leu consists of four general 
subscales assessing physical, functional, emotional, and social 
wellbeing, as well as a fifth leukemia-specific subscale. Higher 
scores on this assessment indicate better QOL. (Appendix II)   
3) Anxiety and depression symptoms: We used the Hospital 
Anxiety and Depression Scale [HADS] to assess depression and 
anxiety symptoms. This highly vetted and widely used instrument 
consists of two subscales which assess anxiety and depression 
symptoms occurring in the past week.69 Higher scores on this 
measure indicate worse distress. Possible scores range from 0 (no 
distress) to 21 (maximal distress), with scores over 7 on the 
subscales representing clinically significant anxiety or depression.  




[PHQ-9] to additionally measure depression severity in the past 2 
weeks. This highly-vetted and widely-used instrument is a set of 9 
questions that targets the frequency of different depression 
symptoms, including suicidal ideation.70 Higher scores on this 
measure indicate more frequent depression symptoms, with 
possible scores ranging from 0 (no depression) to 27 (severe 
depression).  
 
Retrospective Medical Chart Review 
EMRs were analyzed for healthcare utilization and EOL outcomes from the point 
of diagnosis to the time of death for all deceased patients, or up to one-year post-
diagnosis for patients who were still living. EMR notes were reviewed for the following 
information: date of AML diagnosis, total number of ED visits, total number of 
hospitalizations, total number of ICU stays, total number of hospitalizations, date of last 
chemotherapy dose received before death, date of death, place of death, and date of 
transition to hospice. The number of days between last chemotherapy dose, last 
hospitalization, hospice admission and death were calculated. All patients included in this 
study were confirmed to be deceased either by EMR status or online obituary. Place of 
death was documented using information provided in obituaries or notes from providers 






Statistical Analysis  
We performed statistical analyses using STATA (v. 14.2). We calculated 
descriptive statistics to assess the distribution of demographic factors, healthcare 
utilization frequencies, and EOL care measures. All variables collected during 
retrospective medical chart review were included except for the number of ED visits and 
route of chemotherapy administration. Number of ED visits was excluded as a variable 
due to discrepancies in the definition of an ED visit between the two studies—data from 
one study included only ED visits that did not result in admission, while the other 
included ED visits that also resulted in admission.  
 We ran unadjusted, univariate logistic regressions to examine the association 
between patient demographic factors, baseline patient-reported outcomes, and binary 
EOL outcomes of interest (hospital death, hospice use, any ICU stay, chemotherapy 
within 30 days of death, hospitalization in the last 7 days of life). We ran unadjusted, 
univariate linear regressions to examine the association between demographics, patient-
reported outcomes, and two continuous outcomes (hospice LOS, total hospitalizations). 
Predictors of interests were defined a priori based on prior literature and included the 
following variables (patient-reported demographics, baseline QOL scores, baseline 
depression scores, baseline anxiety scores). Factors that were associated with outcomes 
of interest with a P < 0.15 were then included in a multivariate logistic regression model 
(hospital death, hospice use, any ICU stay, chemotherapy within 30 days of death, 
hospitalization in the last 7 days of life) and multivariate linear regression model (hospice 




<0.05 to be statistically significant. All models adjusted for receipt of intervention on 
these supportive care studies. Models were also adjusted for intensity of chemotherapy, 
as receipt of intense chemotherapy vs. low-intensity chemotherapy may impact patient 
experiences and outcomes. Given collinearity between QOL and psychological distress, 
they were included in separate models when examining their association with intensity of 
EOL care. Results were reported as odds ratios (ORs) with 95% confidence intervals.  
 
Table 2: Research Studies Used to Select Patients.  
 


















AML patients who 
are ≥ 60 years old  
 
-Ability to read 
questions in English 
or willing to 
complete 
questionnaires with 








or other co-morbid 
disease  
-Failure to complete 
baseline 


























































within 48 hours 





Patient Characteristics  
Out of 168 included patients, the average age was 67.35 with a range of 20.11 to 
100.31. 88.10% of patients identified as white and 36.31% were female. The majority of 
patients were married (75%) and described themselves as being of the Catholic (35.12%) 
or Christian (non-Catholic) faith (35.71%). Most patients had completed degrees after 
high school, with 26.79% listing high school as their highest degree achieved. Income 
levels were widely distributed. The majority of included patients were receiving intensive 
induction therapy for AML (72.62%). 40.48% of included patients were participating at 
the Massachusetts General Hospital (MGH), which was the primary study site for both 
research protocols. Complete patient characteristics are listed in Table 3. 
Table 3: Patient Characteristics.  
Variable   All patients (n=168) 
Age, median (range)  67.35 [20.11, 100.31] 
Female sex   61 (36.31%) 
White race   148 (88.10%) 
Relationship Status 
     Married  
     Single 
     Divorced  
     Widowed 








     Catholic 
     Christin (non-Catholic) 
     Jewish 
     Muslim 










     Other 




     High school 
     College 
     Post-graduate degree 





3 (1.79%)  
Income 
     < 25K 
     25-50K 
     50-100K 
     100-150K 
     >150K 







18 (10.71%)  
Treatment intensity 
     Intensive induction 





     MGH 
     DFCI 
     Duke 
     Penn 






4 (2.38%)  
 
Healthcare Utilization in Patients with AML 
 
The median number of hospitalizations from the time of diagnosis to the time of 
death was 3 (range, 0-12 hospitalizations) for this deceased patient cohort. 78.18% of 
patients had at least one hospitalization within the last month of life, while 66.67% were 
hospitalized within the last week of life. 60 out of 168 patients (35.71%) were admitted to 
the ICU at least once during their hospitalizations. The majority of these patients died in a 
hospital setting (59.52%), while only 30.95% of patients died outside of the hospital. Of 




was unknown for 16 patients (9.52%). 70 out of 168 patients utilized hospice services 
(40.67%), which was defined as either home hospice care, a hospice facility stay, or 
admission to an inpatient hospice service.  The median number of days patients spent in 
hospice care until death was 8 days (range, 0-97 days). The median time of patients’ last 
chemotherapy dose was 28 days before death (range, 0-236 days), but 51.82% of patients 
received chemotherapy in the last month of life. Healthcare utilization data is depicted in 
Table 4.  
 
Table 4: Healthcare Utilization in Patients with AML.  
Variable All patients (n=168) 
No. hospitalizations, median [range] 3 [0-12] 
ICU admissions: n (%) 60 (35.71%) 
















Hospice utilized: n (%) 70 (40.67%) 
Time from last chemotherapy does to death, median [range] 28 [0-236] 
Time from last hospitalization to death, median [range] 0 [0-441] 
Hospice LOS, median [range] 8 [0-97] 
Percentage receiving chemotherapy within last 30 days of life 51.82% 
Percentage hospitalized within the last 30 days of life  78.18% 




Associations with Intense EOL Care  
In multivariate analyses, we found several patient-reported baseline 
characteristics that were associated with high healthcare utilization and intense care at the 
EOL. Due to collinearity between QOL and psychological distress, these factors were 
included in separate models for any analyses in which both appeared to be related 
through univariate analyses (Associations with Hospital Death, Associations with 
Hospitalization in the Last 7 Days of Life).  
 
Associations with Chemotherapy Use in the Last 30 Days of Life   
 Tables 15 and 16 depict the associations between patient-reported outcomes and 
chemotherapy use in the last 30 days of life. Higher depression scores at baseline were 
significantly associated with receipt of chemotherapy in the last 30 days of life ([HADS] 
OR=1.102, SE=0.053, P=0.042). There were no significant associations with baseline 
QOL, baseline anxiety, or demographic factors.  
Associations with Hospitalization in the Last 7 Days of Life  
Tables 17 and 18 depict the associations between patient-reported outcomes and 
hospitalization in the last 7 days of life. All three of our outcomes of interest were 
associated with this facet of intense EOL care. Patients who report higher levels of 
education (OR=1.538, SE=0.240, P=0.006) and higher baseline depression scores ([PHQ-
9] OR=1.089, SE=0.042, P=0.028) had higher odds of being hospitalized in the last 7 
days of life. On the other hand, patients who had higher baseline QOL scores had lower 




Associations with Hospice Use  
Tables 7 and 8 depict the associations between patient-reported outcomes and 
hospice use. Patients who had higher levels of education had lower odds of using hospice 
at the EOL (OR=0.356, SE=0.163, P=0.024). Age, baseline QOL, and baseline anxiety 
symptoms were associated with hospice use in univariate analyses, but they were not 
statistically significant in multivariate analyses.  
Associations with Death in the Hospital  
Tables 5 and 6 depict the associations between patient-reported outcomes and 
death in the hospital. Patients who reported higher levels of education had higher odds of 
dying in the hospital (OR=1.479, SE=0.234, P=0.013). Additionally, higher baseline 
anxiety symptoms were associated with increased odds of dying in a hospital setting, 
though this was not significant (OR=1.090, SE=0.054, P=0.082).  
 
Table 5: Univariate Analysis of Factors Associated with Death in the Hospital.  
Variable OR SE P 
Hospital Death  
Age 0.94 0.02 0.001 
Female sex 1.20 0.42 0.596 
Married 0.98 0.41 0.975 
Non-intensive chemo 0.34 0.13 0.004 
Education 
     High School 
     College 













Baseline QOL 0.98 0.01 0.023 
Baseline anxiety 1.11 0.049 0.020 
Baseline depression 1.04 0.046 0.399 







Table 6: Multivariate Analysis of Factors Associated with Death in the Hospital.  
Hospital Death:  
Model 1- QOL Model 2- Mood 
Variable OR SE P Variable OR SE P 
Age 0.955 0.024 0.071 Age 0.957 0.024 0.083 
Chemotherapy 0.723 0.368 0.524 Chemotherapy 0.681 0.343 0.445 
Palliative Care 
Arm 
1.940 1.010 0.203 Palliative Care 
Arm 
1.943 1.004 0.199 
Education 1.479 0.234 0.013 Education 1.498 0.236 0.010 
Baseline QOL 0.985 0.009 0.110 Baseline anxiety 1.090 0.054 0.082 
 
Table 7: Univariate Analysis of Factors Associated with Hospice Use.  
Variable OR SE P 
Hospice Use 
Age 1.03 0.014 0.050 
Female sex 0.69 0.22 0.262 
Married 0.70 0.26 0.338 
Non-intensive chemo 1.83 0.65 0.086 
Education 
     High school 
     College 













Baseline QOL 1.00 0.01 0.227 
Baseline anxiety 0.95 0.03 0.186 
Baseline depression 0.97 0.04 0.527 
PHQ-9 0.99 0.03 0.895 
 
Table 8: Multivariate Analysis of Factors Associated with Hospice Use.  
Hospice Use:  
Variable OR SE P 
Age 1.021 0.017 0.204 
Chemotherapy Intensity 1.229 0.528 0.631 
Palliative Care Arm 0.620 0.250 0.235 
Education 
     1 
     2 
















Table 9: Univariate Analysis of Factors Associated with Hospice LOS. 
Variable OR SE P 
Hospice LOS 
Age 0.02 0.01 0.051 
Female sex -0.09 0.30 0.769 
Married 0.48 0.28 0.084 
Non-intensive chemo 0.25 0.28 0.366 
Education 
     High school 
     College 













Baseline QOL -0.003 0.005 0.575 
Baseline anxiety 0.035 0.031 0.264 
Baseline depression 0.007 0.030 0.856 
PHQ-9 -0.009 0.026 0.723 
 
Table 10: Multivariate Analysis of Factors Associated with Hospice LOS. 
Hospice LOS:   
Variable Coef. SE P 
Age 0.014 0.011 0.230 
Palliative Care Arm -1.066 0.456 0.019 
Relationship status: Married 0.546 0.282 0.053 
 
Table 11: Univariate Analysis of Factors Associated with Total Hospitalizations.  
Variable OR SE P 
Total Hospitalizations  
Age -0.001 0.004 0.666 
Female sex -0.025 0.117 0.826 
Married -0.169 0.140 0.227 
Non-intensive chemo 0.05 0.128 0.671 
Education 
     High school 
     College 













Baseline QOL 0.0006 0.002 0.807 
Baseline anxiety -0.017 0.010 0.181 
Baseline depression -0.006 0.014 0.667 









Table 12: Multivariate Analysis of Factors Associated with Total Hospitalizations.  
Total Hospitalizations:   
Variable Coef. SE P 
Age -0.005 0.011 0.192 
Palliative Care Arm -0.183 0.123 0.137 
Baseline anxiety -0.020 0.013 0.116 
 
Table 13: Univariate Analysis of Factors Associated with ICU Stays. 
Variable OR SE P 
ICU Usage  
Age 0.98 0.01 0.207 
Female sex 1.09 0.37 0.793 
Married 0.99 0.38 0.983 
Non-intensive chemo 0.40 0.16 0.023 
Education 
     High school 
     College 













Baseline QOL 0.99 0.007 0.282 
Baseline anxiety 1.008 0.04 0.817 
Baseline depression 0.969 0.04 0.460 
PHQ-9 1.08 0.03 0.791 
 
Table 14: Multivariate Analysis of Factors Associated with ICU Stays. 
ICU Stays:   
Variable OR SE P 
Palliative Care Arm 1.058 0.407 0.884 
Chemotherapy Intensity 0.408 0.156 0.093 
 
Table 15: Univariate Analysis of Factors Associated with Chemotherapy Use in the 
Last 30 Days of Life. 
Variable OR SE P 
Chemo Use in Last 30 Days  
Age 0.99 0.014 0.956 
Female sex 1.19 0.43 0.625 
Married 1.56 0.64 0.272 
Non-intensive chemo 1.03 0.38 0.931 
Education 










     College 







Baseline QOL 0.99 0.007 0.381 
Baseline anxiety 1.07 0.043 0.109 
Baseline depression 1.08 0.049 0.087 
PHQ-9 1.04 0.03 0.197 
 
Table 16: Multivariate Analysis of Factors Associated with Chemotherapy Use in 
the Last 30 Days of Life. 
Chemo Use in Last 30 Days: 
Variable OR SE P 
Age 1.011 0.016 0.478 
Palliative Care Arm 2.350 1.051 0.056 
Baseline depression 1.102 0.053 0.042 
 
Table 17: Univariate Analysis of Factors Associated with Hospitalization in the Last 
7 Days of Life.  
Variable OR SE P 
Hospitalization in Last 7 Days 
Age 0.96 0.01 0.022 
Female sex    
Married 1.55 0.59 0.244 
Non-intensive chemo 0.39 0.14 0.011 
Education 
     High school 
     College 












Baseline QOL 0.976 0.012 0.057 
Baseline anxiety 1.04 0.04 0.269 
Baseline depression 1.07 0.048 0.110 












Table 18: Multivariate Analysis of Factors Associated with Hospitalization in the 
Last 7 days of Life.  
Hospitalization in the last 7 days:  
Model 1- QOL Model 2- Mood 
Variable OR SE P Variable OR SE P 
Age 0.972 0.020 0.157 Age 0.969 0.020 0.117 
Education 1.538 0.240 0.006 Education 1.577 0.251 0.004 
Baseline QOL 0.976 0.009 0.009 Baseline 
depression 
1.089 0.042 0.028 
Palliative Care 
Arm 
2.055 1.015 0.145 Palliative Care 
Arm 
2.126 1.039 0.123 
Chemotherapy 
Intensity 
0.622 0.296 0.318 Chemotherapy 
Intensity 










 In this retrospective analysis, we examined the rates of healthcare utilization of 
168 deceased patients with AML in order to determine the intensity of their EOL care. 
We then examined the relationships between patient factors, baseline QOL and mood, 
with intensity of EOL care.  We demonstrate that patients with AML experience high 
rates of healthcare utilization and thus often experienced intense EOL care, as expected 
from past studies of patients with hematologic malignancies. We observed that patients 
with AML experience a median of 3 hospitalizations from diagnosis to death (range, 0-
12), 66.7% were hospitalized within the last 7 days of life, and over 50% received 
chemotherapy in the last 30 days of life. Additionally, around 36% staying in the ICU at 
some point, nearly 60% died in the hospital, and only 40.67% utilized hospice services.   
Patients’ education levels, baseline QOL scores, and baseline depression scores 
were found to be associated with EOL care outcomes. Specifically, higher education, 
lower baseline QOL, and higher depression scores were found to be significantly 
associated with more intense EOL care indicators. Patients with higher education had 
higher odds of dying in the hospital and being hospitalized in the last week of life, while 
they also had lower odds of using hospice. Patients reporting higher baseline depression 
symptoms had a higher likelihood of receiving chemotherapy in the last 30 days of life 
and of being hospitalized in the last 7 days of life. Higher baseline QOL scores were 
associated with lower odds of being hospitalized in the last 7 days of life. These findings 




suggest the possibility of streamlining EOL care improvement interventions by focusing 
on the experiences of patients highest at risk.  
 
Patients with AML are Likely to Experience Intense EOL Care  
This is the largest study to date examining factors associated with intensity of 
EOL care for patients with AML. Our findings are consistent with prior, smaller 
investigations, underscoring the high intensity of EOL care in this population. This study, 
along with others, demonstrates that patients with AML experience high rates of 
chemotherapy use in the last month of life, frequent hospitalizations and ICU admissions 
in the last month of life, high likelihood of dying in the hospital, and low hospice 
utilization.8, 44  
Patients with AML experience high symptom burden and toxicities from 
treatment, which likely leads to the high frequencies of hospitalizes and ICU stays in this 
population. The AML disease trajectory is often unpredictable, so patients are often 
receiving more intense, highly toxic treatments later in life.31  Additionally, patients with 
AML often require blood products and intravenous antibiotics at the EOL, which leads to 
higher amounts of healthcare utilization and lower rates of hospice referral as many 
hospice facilities cannot meet these needs.31, 44  Supporting this, previous studies have 
also shown that transfusion dependent patients are more likely to die in the ICU and less 
likely to die in hospice.44 Lower rates of hospice utilization in this population could also 
be due to difficulty identifying a specific “EOL phase” in the AML trajectory, as a decent 




Finally, studies have shown that patients with hematologic malignancies, 
including AML, have prognostic understanding as an important challenge in dealing with 
their treatment, and that these patients have misperceptions about their treatment risks 
and benefits.31, 55 Specifically, patients have been shown to overestimate their prognosis 
with AML, which is correlated with preference for intense medical care at the EOL.31, 57.   
 
Education Levels and EOL Care  
 To our knowledge, this is the first study to examine the relationship between 
patient-reported education level and intensity of EOL care in the AML patient 
population. We observed an association between patients’ education levels and their 
likelihood for dying in the hospital, being hospitalized in the last week of life, and using 
hospice care. It is possible that this relationship could be mediated by proximity to 
academic medical centers. As Earle et al. found, patients receiving care at teaching 
hospitals or in regions with higher densities of teaching hospitals are more likely to 
experience intense EOL care.5 It is possible that more highly educated patients reside 
nearer to these centers, who or choose to receive care in these hospitals. There could also 
be a bias in the number of intensive treatment options presented to patients with higher 
health literacy levels, or in the way options are understood during goals-of-care 
conversations. Future studies are needed to explore the possible discrepancies in AML 
treatment and EOL care for patients of varying health literacy levels or demographic 





QOL and EOL Care  
Our results demonstrate that higher baseline QOL scores are associated with a 
lower likelihood of experiencing intensive EOL care indicators. This is in line with one 
systematic review study which reported that low baseline health-related QOL scores in 
AML patients were predictive of poorer outcomes.45 It is logical that poor outcomes 
would likely lead to more interactions with acute healthcare settings, and thus more 
intense care.  
Additionally, a large aspect of QOL is symptom burden, with patients 
experiencing high symptom burden having lower QOL scores. Patients with high 
symptom burden or poorly controlled symptoms are also more likely to present to an 
acute healthcare setting. Nipp et al. observed that in solid tumor populations, higher 
symptom burdens were significantly associated with longer hospital LOS, unplanned 
hospital readmissions within 90-days, and death or readmission within 90 days.6  
Another study by Oliva et al. found that QOL scores at diagnosis were related to 
eventual survival. Patients with lower QOL scores had shorter survival compared to those 
with higher QOL scores. In this study, the predictive value of these scores on survival 
was mainly observed for patients over 70, which is in line with the cohort examined in 
this study (median age 67.35).60 Finally, QOL has been shown to worsen with proximity 
to death in AML patients.44 Thus, it is logical that a lower baseline QOL may become 
even lower towards the EOL, which could have an effect on overall survival and intensity 





Psychological Distress and EOL Care  
 This study indicated a relationship between psychological distress at baseline and 
later intense EOL care. Specifically, higher depression scores at baseline were associated 
with higher odds of being hospitalized in the last week of life and higher odds of 
receiving chemotherapy in the last month of life. Higher anxiety scores at baseline were 
associated with higher risk of dying in the hospital, though this was not significant.  
Prior studies have suggested that depression is associated with poor overall survival and 
increased healthcare utilization in patients with chronic illness.61-64 In a study of solid 
tumor patients, Nipp et al. also found a relationship between patient-reported depression 
scores, longer hospital LOS, and death or readmission within 90 days.6 Similarly, in a 
study of 5055 cancer patients, patients suffering from depression were more likely to 
have healthcare visits, ED visits, hospitalizations, and 30-day hospital readmission.61 
Additionally, elevated depression symptoms may be predictive of higher mortality among 
cancer patients.63, 64 Given these suggested relationships, it is logical that elevated 
psychological distress, with a particular emphasis on depression symptoms, would lead to 
more intense EOL care in patients with AML.  
 
The Importance of Palliative Care and Hospice Care Utilization  
 The findings of this study reiterate the exceptional need for improved access to, 
utilization of, and early integration of palliative care and hospice for the AML population 
facing the EOL. There are many barriers to implementing the most beneficial use of these 




unpredictable, which leads to late use of intense treatments such as chemotherapy, a lack 
of prognostic understanding on the part of the patient, and late referral to hospice.31 
Culturally, providers caring for these patients have reported unrealistic expectations in 
terms of prognosis,65 discomfort discussing death and hospice referral with patients, and a 
higher likelihood to continue prescribing cancer therapy rather than comfort care.66 
Finally, AML patients face unique barriers to hospice care, including a need for blood 
product support, which is not always available outside of the hospital setting.31, 44 Despite 
these barriers, patients with AML have a substantial need for supportive care intervention 
through palliative care and hospice care at the EOL.31   
 Palliative care services have been shown to reduce symptom burden, improve 
QOL, and reduce psychological distress. In a study of 160 AML patients receiving usual 
leukemia care or integrated palliative care, those receiving palliative care reported better 
QOL and lower depression and anxiety. Additionally, patients in this study were more 
likely to discuss EOL care preferences with providers and were less likely to receive 
chemotherapy near the EOL.67 Thus, integration of palliative care can lead to less intense 
EOL care, better QOL, and lower psychological distress, which this study showed to be 
associated with intense EOL care.  
Knowledge of patient characteristics that may be associated with later intense 
EOL care can help identify patients that may be especially at need for these services. 
Early use of these services can help direct care plans that are in line with the patient’s 
needs and desires, as well as help reduce the symptom burden of these patients. This 




on, which supports the use of QOL-improving health interventions early in AML care. 
This study shows that QOL and psychological distress and related to EOL outcomes, 
which underlines the need for attention to these aspects of patient’s lives.  
 
Limitations   
This study had several important limitations to consider. First, patients included in 
this analysis were drawn from two studies at large academic medical centers. Thus, this 
analysis only captures patients receiving care at such institutions and does not include 
patients who either have limited access to academic centers, or who choose to receive 
care elsewhere. These medical centers were located in several different parts of the US, 
which helps the generalizability of this study, but the sample is still limited to a subset of 
patients.  In terms of generalizability, this cohort of patients was also lacking in some 
subsets of diversity. The majority of patients were white (88.10%) and married (75%). It 
is unknown how many patients were ethnically Hispanic or non-Hispanic. Over a quarter 
of included patients held a post-graduate degree (26.19%). Because of these factors, 
findings may not be generalizable to all AML patients.  
Second, we were unable to ascertain the EOL outcomes of patients who 
transferred care and did not receive EOL care at our institution, or at one of the 
institutions participating in the included studies. Because of this limitation, it is likely that 
healthcare utilization was even higher than observed by this study, as further interactions 




Third, this analysis did not include information on the number of ED visits 
patients experienced. Though this information was collected, it was not included due to a 
discrepancy in the definition of an ED visit between the two studies included. Though ED 
visit rates are only one of multiple intense EOL care indicators, having this information 
would further the knowledge about what kind of healthcare interactions patients with 
AML experience at the EOL.  
Finally, our study examined the associations between the intensity of EOL care, 
patient demographics, and baseline psychological distress. Through our analysis, we did 
observe significant relationships, however we are unable to determine the causality of 
these findings due to the correlational nature of this study. Additional causal research is 





 In conclusion, this study reiterated that patients with AML have high healthcare 
utilization and are likely to experience intense EOL care. Despite this, the usage of 
hospice care services remains subpar, with less than half of patients observed to utilize 
these services at the EOL. Furthermore, the median hospice LOS was 8 days before 
death, indicating that if hospice care is initiated, it does not occur until close to death. 
Given the established benefit of symptom management and comfort-focused care as 
hospice provides, this may mean that patients with AML could further benefit from 
earlier integrated hospice care.  
 There are several factors that may be predictive of a higher risk of intense EOL 
care. Specifically, this study shows that patients with high education levels may have 
higher risk of being hospitalized at the EOL and dying in the hospital, as well as lower 
likelihood of utilizing hospice care. Patients’ QOL and psychological distress levels may 
also be important indicators of later intense EOL care, as higher baseline QOL is 
associated with lower risk of hospitalization at the EOL, while higher depression 
symptoms at baseline are associated with higher risk of hospitalization at the EOL. 
Higher depression scores may also be associated with increased risk of late chemotherapy 
usage.  
 These findings suggest that there are multiple patient characteristics that may be 
useful for identifying patients at higher risk for later intense EOL care. Earlier 
identification of these patients may aid in planning for the most appropriate EOL care, 




preferences. Identifying those at high risk earlier and planning for the most appropriate 
care may also help decrease the amount of unnecessary hospitalizations and healthcare 
interactions near the EOL, reducing the financial burden on patients, families, and 
healthcare systems.  
 Moving forward, studies are needed to further explore potential factors that may 
be associated with increased risk of intense EOL care, as well as studies to examine the 
benefits and outcomes of earlier identification. Specifically, studies are needed to 
demonstrate the impact of earlier identification on later healthcare utilization and EOL 






APPENDIX I: Demographics Questionnaire 









¨ Hispanic or Latino 
¨ Not Hispanic or Latino 
 
3. Race (please check all that apply) 
¨ American Indian or Alaskan native 
¨ Asian 
¨ African American or Black 
¨ Native Hawaiian or other Pacific 
Islander 
¨ White 




¨ Catholic Christian 






¨ Other (please 
specify)_______________ 
 
5. Current relationship status 
¨ Married or living with someone as if 
married 
¨ Non-cohabiting relationship 
¨ Single, never married 
¨ Divorced/Separated 




6. Please indicate your highest or current 
education level 
¨ 12th grade or less 
¨ High school graduate or GED 
¨ 2 years of college/AA 
degree/Technical    school training 
¨ College graduate (BA or BS) 
¨ Masters degree 
¨ Doctorate/Medical degree/Law degree 
 
7. What is your annual combined 
household income? 
¨ Less than $25,000 
¨ $25,000 – 50,000 
¨ $50,000 -100,000 
¨ $100,000 – 150,000 
¨ Greater than $150,000 
 
8. Please indicate who you live with (you 
may check more than one box) 
¨ By myself 
¨ Partner/Spouse 
¨ Roommate/Friend 
¨ Children under 18 
¨ Children over 18 
¨ Group home/assisted living/nursing 
home 
¨ Parent 
¨ Other (please specify) 
_____________ 
 
9. Current employment status 
(please check all that apply):  
¨ Employed (full-time or part-time) 
¨ Caring for home or family (not 
currently working and not looking for 
paid work) 
¨ Unemployed and looking for work 
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